Canakinumab in adults with steroid-refractory pyoderma gangrenosum

British Journal of Dermatology

Volumn 173, Issue 5, 2015, Pages 1216-1223

  Kolios, A G A ^a,b   Maul, J T ^a   Meier, B ^a   Kerl, K ^a   Traidl Hoffmann, C ^c   Hertl, M ^d   Zillikens, D ^e   Rocken M ^f   Ring, J ^c   Facchiano, A ^g   Mondino, C ^h   Yawalkar, N ⁱ   Contassot, E ^a   Navarini, A A ^a   French, L E ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e UNIVERSITY OF LÜBECK   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

^g LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^h REGIONAL HOSPITAL OF LUGANO   (Switzerland)

ⁱ UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CANAKINUMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; DOXYCYCLINE; ETANERCEPT; GAMMA INTERFERON; IL 36ALPHA PROTEIN; IL 36GAMMA; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MYCOPHENOLATE MOFETIL; PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY; STEROID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FATIGUE; FEMALE; GENITAL ULCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PYODERMA GANGRENOSUM; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REMISSION; SKIN BIOPSY; STEROID REFRACTORY PYODERMA GANGRENOSUM; TREATMENT DURATION; YOUNG ADULT; CLINICAL TRIAL; CUTANEOUS DRUG ADMINISTRATION; DRUG ADMINISTRATION; DRUG RESISTANCE; METABOLISM; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANTIBODIES, MONOCLONAL; CYTOKINES; DERMATOLOGIC AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; PYODERMA GANGRENOSUM; STEROIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84983095461     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14037     Document Type: Article

References (40)

1. Wollina U, Haroske G,. Pyoderma gangraenosum. Curr Opin Rheumatol 2011; 23: 50-6.
2. Ruocco E, Sangiuliano S, Gravina AG, et al,. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol 2009; 23: 1008-17.
3. Binus AM, Qureshi AA, Li VW, Winterfield LS,. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 2011; 165: 1244-50.
4. Shahi V, Wetter DA,. Pyoderma gangrenosum associated with solid organ malignancies. Int J Dermatol 2015; 54: e351-7.
5. DeFilippis EM, Feldman SR, Huang WW,. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol 2015; 172: 1487-97.
6. Weizman AV, Huang B, Targan S, et al,. Pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort study. J Cutan Med Surg 2014; 18: 361.
7. Gade M, Studstrup F, Andersen AK, et al,. Pulmonary manifestations of pyoderma gangrenosum: 2 cases and a review of the literature. Respir Med 2015; 109: 443-50.
8. Sakata KK, Penupolu S, Colby TV, et al,. Pulmonary pyoderma gangrenosum without cutaneous manifestations. Clin Respir J 2014; DOI: 10.1111/crj.12240.
9. Mercer JM, Kuzel P, Mahmood MN, Brassard A,. Fatal case of vulvar pyoderma gangrenosum with pulmonary involvement: case presentation and literature review. J Cutan Med Surg 2014; 18: 424-9.
10. Satoh M, Yamamoto T,. Genital pyoderma gangrenosum: report of two cases and published work review of Japanese cases. J Dermatol 2013; 40: 840-3.
11. Bouchaud G, Gehrke S, Krieg C, et al,. Epidermal IL-15Rα acts as an endogenous antagonist of psoriasiform inflammation in mouse and man. J Exp Med 2013; 210: 2105-17.
12. Craig FF, Thomas KS, Mitchell EJ, et al,. UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone vs. ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial. Trials 2012; 13: 51.
13. Brooklyn TN, Dunnill MG, Shetty A, et al,. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006; 55: 505-9.
14. Miller J, Yentzer BA, Clark A, et al,. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol 2010; 62: 646-54.
15. Wollina U,. Pyoderma gangrenosum-a review. Orphanet J Rare Dise 2007; 2: 19.
16. D'Inca R, Fagiuoli S, Sturniolo GC,. Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine. Ann Intern Med 1998; 128: 783-4.
17. Sinagra E, Orlando A, Renna S, et al,. Multifocal pyoderma gangrenosum resistant to infliximab in active ulcerative colitis: don't forget the role of cyclosporin. Inflamm Bowel Dis 2012; 18: E1594-5.
18. Langan SM, Groves RW, Card TR, Gulliford MC,. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol 2012; 132: 2166-70.
19. Al Ghazal P, Dissemond J,. Therapy of pyoderma gangrenosum in Germany: results of a survey among wound experts. J Dtsch Dermatol Ges 2015; 13: 317-24.
20. Ye MJ, Ye JM,. Pyoderma gangrenosum: a review of clinical features and outcomes of 23 cases requiring inpatient management. Dermatol Res Pract 2014; 2014: 461467.
21. Hasselmann DO, Bens G, Tilgen W, Reichrath J,. Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature. J Dtsch Dermatol Ges 2007; 5: 560-4.
22. Wolff K, Goldsmith LA, Katz SI,. Fitzpatrick's Dermatology in General Medicine. New York: McGraw-Hill, 2010.
23. Yu JW, Fernandes-Alnemri T, Datta P, et al,. Pyrin activates the ASC pyroptosome in response to engagement by autoinflammatory PSTPIP1 mutants. Mol Cell 2007; 28: 214-27.
24. Yu JW, Farias A, Hwang I, et al,. Ribotoxic stress through p38 mitogen-activated protein kinase activates in vitro the human pyrin inflammasome. J Biol Chem 2013; 288: 11378-83.
25. Zeeli T, Padalon-Brauch G, Ellenbogen E, et al,. Pyoderma gangrenosum, acne and ulcerative colitis in a patient with a novel mutation in the PSTPIP1 gene. Clin Exp Dermatol 2015; 40: 367-72.
26. Meng G, Zhang F, Fuss I, et al,. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 2009; 30: 860-74.
27. Quaglino P, Fava P, Caproni M, et al,. Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immuno-pathology group. J Eur Acad Dermatol Venereol 2015; DOI: 10.1111/jdv.13100.
28. Caproni M, Antiga E, Volpi W, et al,. The Treg/Th17 cell ratio is reduced in the skin lesions of patients with pyoderma gangrenosum. Br J Dermatol 2015; 173: 275-8.
29. Marzano AV, Fanoni D, Antiga E, et al,. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome. Clin Exp Immunol 2014; 178: 48-56.
30. Jaeger T, Andres C, Grosber M, et al,. Pyoderma gangrenosum and concomitant hidradenitis suppurativa-rapid response to canakinumab (anti-IL-1β). Eur J Dermatol 2013; 23: 408-10.
31. Geusau A, Mothes-Luksch N, Nahavandi H, et al,. Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA-like syndrome responding to canakinumab treatment. JAMA Dermatol 2013; 149: 209-15.
32. Ter Haar N, Lachmann H, Ozen S, et al,. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013; 72: 678-85.
33. Ahronowitz I, Harp J, Shinkai K,. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 2012; 13: 191-211.
34. Saracino A, Kelly R, Liew D, Chong A,. Pyoderma gangrenosum requiring inpatient management: a report of 26 cases with follow up. Australas J Dermatol 2011; 52: 218-21.
35. Dinarello CA, Simon A, van der Meer JW,. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11: 633-52.
36. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al,. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25.
37. Brenner M, Ruzicka T, Plewig G, et al,. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol 2009; 161: 1199-201.
38. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T,. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012; 66: 409-15.
39. Gerard AJ, Feldman SR, Strowd L,. Quality of life of patients with pyoderma gangrenosum and hidradenitis suppurativa. J Cutan Med Surg 2015; 19: 391-6.
40. Puzenat E, Bronsard V, Prey S, et al,. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature. J Eur Acad Dermatol Venereol 2010; 24 (Suppl. 2): 10-16.